Enoxaparin Dosing in DVT

Treatment Doses (Acute DVT)

• The 1 mg/kg q12h regimen is the most widely used and evidence-supported regimen.
• The 1.5 mg/kg once daily is an acceptable alternative for uncomplicated outpatient DVT without PE.
• Continue for a minimum of 5 days and until INR is ≥ 2.0 for ≥ 24 hours if transitioning to warfarin, or until a DOAC reaches full therapeutic effect.

Prophylaxis Doses (DVT Prevention)

Special Populations

• Treatment dose: reduce to 1 mg/kg SC once daily (instead of twice daily)
• Prophylaxis dose: reduce to 20 mg SC once daily
• Anti-Xa monitoring is recommended in severe renal impairment
• National Kidney Foundation Primer on Kidney Diseases, 8e

• Use actual body weight for dose calculation; capping at 150 mg per dose is sometimes done but not universally agreed upon - monitor with anti-Xa levels if weight > 100 kg or BMI > 40.

• LMWHs including enoxaparin are the preferred agents for VTE treatment and prophylaxis in pregnancy (warfarin is teratogenic).
• Dose: 1 mg/kg SC q12h for treatment; 40 mg SC once daily for prophylaxis.
• Dose increases may be needed in the 2nd and 3rd trimester due to increased volume of distribution.

• 1 mg/kg SC q12h (same treatment dose, but reduce to 1 mg/kg once daily if CrCl < 30)
• The Washington Manual of Medical Therapeutics

Monitoring

• Routine anti-Xa monitoring is not required for standard-weight patients with normal renal function.
• Anti-Xa levels should be checked (peak 4 hours post-injection) in: renal impairment, obesity, pregnancy, extremes of weight, or unexpected bleeding/clotting.
• Target anti-Xa range: 0.6-1.0 IU/mL (q12h dosing); 1.0-2.0 IU/mL (once-daily dosing).
• No aPTT monitoring needed (unlike UFH).

Key Notes

• Enoxaparin primarily inhibits factor Xa (and to a lesser extent thrombin), giving a more predictable anticoagulant effect than UFH.
• HIT (heparin-induced thrombocytopenia) risk is lower with LMWH than UFH, but not zero - monitor platelet counts.
• Reversal: Protamine sulfate partially reverses enoxaparin (neutralizes ~60% of anti-Xa activity); no complete reversal agent like UFH.
• Avoid or use with extreme caution in CrCl < 15 mL/min (significant accumulation risk).

LMWH Dosing in DVT

What are LMWHs?

Treatment Doses (Acute DVT)

Note: 1 mg of enoxaparin = 100 IU. All doses are weight-based and given subcutaneously (SC).

• The twice-daily regimens are generally preferred for inpatients or high-risk/complicated DVT.
• The once-daily regimens are convenient for outpatient management of uncomplicated DVT.
• Treatment should continue for a minimum of 5 days and until the INR is ≥ 2.0 for ≥ 24 hours if bridging to warfarin, or until a DOAC takes full effect.

Prophylaxis Doses (DVT Prevention)

Special Populations and Dose Adjustments

• Anti-Xa monitoring is strongly recommended.
• For enoxaparin: reduce treatment dose to 1 mg/kg SC once daily.
• Avoid LMWH (or use with extreme caution and monitoring) if CrCl < 15 mL/min due to drug accumulation and bleeding risk.

• Weight-adjusted dosing may be inappropriate as LMWH has altered volume of distribution.
• Anti-Xa monitoring recommended; some cap enoxaparin at 150 mg/dose.
• Goldman-Cecil specifically flags anti-Xa monitoring in this population.

• LMWHs are the preferred anticoagulants in pregnancy (warfarin is teratogenic).
• Treatment dose: 1 mg/kg enoxaparin SC q12h or weight-based dalteparin/tinzaparin.
• Doses may need adjustment as weight increases through gestation.
• Anti-Xa monitoring (peak level 4h post-injection, target 0.6-1.0 IU/mL for q12h dosing) is recommended.

• LMWH (especially dalteparin) has historically been preferred over warfarin in cancer patients.
• Recent meta-analysis (PMID 40578592) shows DOACs are now comparable or superior to LMWH in cancer-associated thrombosis for many patients.

Monitoring

Advantages over UFH

• More predictable pharmacokinetics (subcutaneous, no IV line needed)
• No routine monitoring required
• Lower risk of heparin-induced thrombocytopenia (HIT) - though still possible
• Can be used for outpatient DVT treatment
• Less binding to plasma proteins

Current Guidelines Perspective

• Pregnancy
• Severe renal impairment where DOACs are contraindicated (CrCl < 15-30 mL/min depending on agent)
• Cancer-associated DVT (if DOAC not suitable)
• Patients on interacting medications
• When bridging to warfarin
• Goldman-Cecil Medicine International Edition, Table 68-7
• National Kidney Foundation Primer on Kidney Diseases, 8e